# Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

> **NCT03654768** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 81 (actual)

## Conditions studied

- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nilotinib
- **DRUG:** Ruxolitinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT03654768
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-24
- **Primary completion:** 2024-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654768, "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03654768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*